Updated Jul 16, 2026
Ciaramella Giuseppe has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $4.10M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-22 | BEAM | Beam Therapeutics Inc. | M — Option exercise | 29.0K | $1.03 | $30K |
| 2026-06-22 | BEAM | Beam Therapeutics Inc. | M — Option exercise | 6.5K | $0.67 | $4K |
| 2026-04-06 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 11.8K | $24.58 | $290K |
| 2026-04-02 | BEAM | Beam Therapeutics Inc. | A — Grant or award | 40.0K | $0.00 | |
| 2026-02-26 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 35.0K | $32.00 | $1.12M |
| 2026-02-26 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 35.0K | $17.00 | $595K |
| 2024-12-19 | BEAM | Beam Therapeutics Inc. | M — Option exercise | 53.5K | $0.67 | $36K |
| 2024-11-08 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 51.1K | $26.36 | $1.35M |
| 2024-10-16 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 51.1K | $26.27 | $1.34M |
| 2024-10-16 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 1.5K | $7.22 | $11K |
| 2024-10-16 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 13.0K | $4.22 | $55K |
| 2024-10-16 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 27.3K | $0.67 | $18K |
Ciaramella Giuseppe is a corporate insider — currently tracked as Insider of Beam Therapeutics Inc. (BEAM). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($4.10M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Ciaramella Giuseppe profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.